SCHEMBL5260053

SCHEMBL5260053

Cc1cc(C)nc(Nc2cc(-c3nc4ccccc4s3)ccc2C)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.63
SMN1; SMN2 Q16637 6/20 0.58
NPC1 O15118 3/20 0.58
RAB9A P51151 3/20 0.58
MEN1 O00255 8/20 0.53
KMT2A Q03164 8/20 0.53
MAPT P10636 6/20 0.53
ALDH1A1 P00352 6/20 0.53
CYP3A4 P08684 4/20 0.53
CYP2C9 P11712 3/20 0.53
RXFP1 Q9HBX9 2/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2C19 P33261 2/20 0.53
APP P05067 4/20 0.52
NPSR1 Q6W5P4 4/20 0.52
KDM4E B2RXH2 5/20 0.50
HPGD P15428 3/20 0.50
LMNA P02545 4/20 0.49
GLA P06280 2/20 0.49
GAA P10253 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5258486 0.90 SMN1; SMN2 (0.58) TP53SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL5260609 0.88 RAB9A (0.55) TP53SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL5263632 0.83 APP (0.63) TP53SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL5259397 0.81 SMN1; SMN2 (0.60) TP53SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL14156493 0.78 MAPT (0.65) TP53SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL29935542 0.75 KDM4E (0.64) TP53SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL16080077 0.74 APP (0.69) TP53SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL31471859 0.74 APP (0.65) TP53SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL2240330 0.74 APP (0.65) TP53SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL16602324 0.74 TP53 (0.75) TP53SMN1; SMN2NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007009524-A1 2-ARYLBENZOTHIAZOLES AND USES THEREOF 4SC AG (DE) 2007-01-25 WO disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof NR2E1, NR2E3, NR0B2 TP53 3223/4885SMN1; SMN2 1665/4885NPC1 4075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.